Home / Health / Breakthrough siRNA Therapy Promises Sickle Cell Treatment
Breakthrough siRNA Therapy Promises Sickle Cell Treatment
19 Nov
Summary
- Marrow Therapeutics develops siRNA therapy for sickle cell disease.
- New therapy aims to be as effective as gene therapy without side effects.
- Funding secured to potentially treat patients globally, including Africa.

A new biotech startup, Marrow Therapeutics, based in Watertown, has launched with $173 million in Series A and B funding to develop a novel treatment for sickle cell disease. The company is pursuing an siRNA-based therapy, a different approach than current gene editing treatments.
This innovative therapy aims to deliver similar efficacy to gene therapy but without its significant drawbacks, such as infertility and harsh side effects. Current gene editing treatments involve lengthy and costly processes, limiting accessibility, especially in regions with the highest prevalence of sickle cell disease.
Marrow Therapeutics' approach utilizes short strands of RNA guided by antibodies to target specific genes. The company is optimistic about its potential for global accessibility, with a goal to make the treatment affordable for regions like Africa and Southeast Asia.
The company is currently conducting studies necessary to initiate human trials next year. Beyond sickle cell, Marrow Therapeutics is also exploring therapies for other bone marrow disorders, signaling broader ambitions in hematological treatments.